Table 1.
Randomized controlled trials for the treatment of myocardial infarction in the acute setting using CMR parameters as a primary study endpoint (sorted by date of publication)
| Primary CMR endpoint | Study | Treatment | Number of patients | Year published |
|---|---|---|---|---|
| Myocardial salvage index at days 2-4 | Thiele et al. (LIPSIA-N-ACC study)[48] | High-dose N-acetylcysteine | 251 | 2010 |
| LV endsystolic volume index at 10-14 weeks | Abbate et al.[71] | Interleukin-1 blockade with anakinra | 10 | 2010 |
| LV ejection fraction at 6 months | Wöhrle et al.[72] | Autologous intracoronary bone-marrow cell therapy | 42 | 2010 |
| Myocardial salvage at 3 months | Lonborg et al.[47] | Ischemic postconditioning | 118 | 2010 |
| Infarct size at 4-6 months | Haeck et al.[73] | Proximal embolic protection and thrombus aspiration | 206 | 2010 |
| Infarct size and LV ejection fraction at 90 days | Patel et al. (APEX-AMI trial)[74] | Pexelizumab (anti-C5 complement antibody) | 99 | 2010 |
| LV endsystolic volume index at 24 weeks | Weir et al.[75] | Eplerenone | 100 | 2009 |
| LV ejection fraction at 6 months | Tendera et al. (REGENT study)[76] | Intracoronary infusion of bone-marrow derived selected CD34+CXCR4+ cells versus non-selected mononuclear cells | 200 | 2009 |
| Infarct size at 1 month | Song et al.[77] | Upstream high-dose tirofiban treatment | 2009 | |
| LV ejection fraction at 4 and 12 months | Dill et al.[78] | Intracoronary administration of bone-marrow derived progenitor cells | 54 | 2009 |
| Infarct size after 5 days | Atar et al. (FIRE study)[79] | FX06 | 234 | 2009 |
| Infarct size and microvascular obstruction at 2 days | Thiele et al.[25] | Intracoronary versus intravenous bolus abciximab application | 144 | 2008 |
| Infarct size at 3 days | Hahn et al.[80] | Distal protection device | 39 | 2007 |
| Global and regional myocardial function at 3 months | Engelmann et al.[81] | Granulocyte colony-stimulating factor | 44 | 2006 |
| LV ejection fraction at 6 months | Kang et al. (MAGIC Cell-3-DES trial)[82] | Intracoronary infusion of mobilized peripheral blood stem cells | 96 | 2006 |
| Systolic wall thickening at 6 months | Ripa et al. (STEMMI trial)[83] | Granulocyte colony-stimulating factor | 78 | 2006 |
| LV ejection fraction at 4 months | Janssens[84] | Transfer of autologous bone-marrow derived stem cells in the infarct-related artery | 67 | 2006 |
| Infarct size at 6 months | Thiele et al.[85] | Pre-hospital combination-fibrinolysis plus conventional care versus pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention | 164 | 2005 |
| LV ejection fraction at 6 months | Wollert et al. (BOOST trial)[86] | Intracoronary transfer of autologous bone-marrow cells | 60 | 2004 |
| LV volumes at 6 months | Darasz et al.[87] | Captopril and xamoterol | 70 | 1995 |
Abbreviations: CMR = cardiac magnetic resonance; LV = left ventricular.